Can Antidepressants Be Used to Treat the Schizophrenia Prodrome?: Results of a Prospective, Naturalistic Treatment Study of Adolescents
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This study reports the results of a prospective, naturalistic treatment study of adolescents considered to be in the prodromal (i.e., prepsychotic) phase of schizophrenia. METHOD: Forty-eight adolescents (mean age = 15.8 years) participating in the initial phase of the Recognition and Prevention (RAP) program (1998-2005) were included in the current report. Individuals were selected from the overall sample (N = 152) if they had: (1) displayed attenuated positive symptoms, (2) been treated pharmacologically for at least 8 weeks, and (3) been followed up for at least 6 months (mean follow-up = 30.5 months). RESULTS: Two types of medication were naturalistically prescribed: antidepressants (N = 20) or second-generation antipsychotics (N = 28), with polypharmacy common. The 2 treatment groups did not differ in baseline symptom profiles, with the exception of disorganized thinking, which was more severe in second-generation antipsychotic-treated adolescents. Twelve of the 48 adolescents (25%) developed a psychotic disorder, with all converters having been prescribed second-generation antipsychotics. There were no conversions among antidepressant-treated adolescents (log-rank chi(2) = 7.36, df = 1, p = .007). Treatment outcome, however, was confounded, since 11 of the 12 converters were nonadherent. Adolescents, in general, were more likely to be nonadherent to second-generation antipsychotics (61%, 17/28) than to antidepressants (20%, 4/20; chi(2) = 7.86, p = .005). Improvement in 3 of 5 positive symptoms over time was significant (p < .001) and similar for both medications. Disorganized thought, however, did not improve regardless of treatment. CONCLUSIONS: Nonrandom assignment limits comparisons between antidepressants and anti-psychotics in this study. However, with follow-up, a number of adolescents meeting criteria for prodromal schizophrenia were successfully treated with antidepressants. At present, a substantial number of false positives among the antidepressant-treated subgroup cannot be ruled out. However, the findings suggest that, in some cases, it might be preferable to begin treatment with antidepressants and progress to antipsychotics once symptoms intensify, since adherence to the latter is difficult to maintain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Predicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
Cornblatt, B. A., Auther, A. M., Niendam, T., Smith, C. W., Zinberg, J., Bearden, C. E., & Cannon, T. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm029 · Cited by 630
Self-citationStress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia
Walker, E., Mittal, V., & Tessner, K. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141248 · Cited by 615
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
“Other pharmacological trials of antidepressants [16,86] and aspirin [125] used a naturalistic design and/or are still ongoing.”
BackgroundEarly intervention in psychosis: concepts, evidence and future directions
MCGORRY, P. D., KILLACKEY, E., & YUNG, A. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00182.x · Cited by 581
“We can readily accept that antipsychotics and indeed antidepressants (67) and neuroprotective agents such as omega-3 fatty acids and lithium are legitimate therapies to be further researched, but their use in research should be protocolized within rigorous study designs.”
BackgroundFusar-Poli, P., Cappucciati, M., Borgwardt, S., Woods, S. W., Addington, J., Nelson, B., Nieman, D. H., Stahl, D. R., Rutigliano, G., Riecher-Rössler, A., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2324 · Cited by 440
Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis: The PACE 400 Study
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M., Foley, D. L., Brewer, W. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1270 · Cited by 433
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
Meyer, U., Feldon, J., & Fatemi, S. H. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.001 · Cited by 373
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 372
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Intervention in Individuals at Ultra-High Risk for Psychosis: A Review and Future Directions
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G., Riecher-Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze-Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
McGorry, P. D., Nelson, B., Goldstone, S., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 279
Juster, R.-P., Bizik, G., Picard, M., Arsenault-Lapierre, G., Sindi, S., Trepanier, L., Marin, M.-F., Wan, N., Sekerovic, Z., Lord, C., et al. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000289 · Cited by 268
“reduce the risk of converting to Axis I psychosis (Cornblatt et al., 2007).”
BackgroundMcGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2902 · Cited by 262
Risk Factors for Psychosis: Impaired Social and Role Functioning
Cornblatt, B. A., Carrion, R. E., Addington, J., Seidman, L., Walker, E. F., Cannon, T. D., Cadenhead, K. S., McGlashan, T. H., Perkins, D. O., Tsuang, M. T., et al. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr136 · Cited by 262
Self-citationPrediction and Prevention of Psychosis in Youth at Clinical High Risk
Addington, J., & Heinssen, R. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143146 · Cited by 189
“In addition, alternative pharmacologic approaches should be explored, including antidepressants (Cornblatt et al. 2007b), lithium, and biologics such as glycine (Woods et al. 2006) and essential fatty acids (Amminger et al. 2010).”
BackgroundMethodInfluentialPreti, A., & Cella, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.026 · Cited by 167
Gender Differences in Individuals at High‐Risk of Psychosis: A Comprehensive Literature Review
Barajas, A., Ochoa, S., Obiols, J. E., & Lalucat-Jo, L. (2015) · The Scientific World Journal · doi:10.1155/2015/430735 · Cited by 122
“This clinical syndrome has been termed an at-risk mental state [13], and operationalized criteria—the ultra-high risk (UHR) [14] or clinical high-risk (HR) criteria [15]—have been developed to identify the syndrome.”
BackgroundDu, Y., & Grace, A. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.101 · Cited by 105
Fusar-Poli, P., Frascarelli, M., Valmaggia, L., Byrne, M., Stahl, D., Rocchetti, M., Codjoe, L., Weinberg, L., Tognin, S., Xenaki, L., et al. (2015) · Psychological Medicine · doi:10.1017/s003329171400244x · Cited by 73
“A previous naturalistic study (Cornblatt et al. 2007) found opposite effects for APs and ADs, with no transition in the AD group and 25% transition in the AP group over a mean follow-up time of 30.5 months; a similar finding was also confirmed by an audit in an early OASIS sample (Fusar-Poli et al.…”
ResultInfluentialDeVylder, J. E., Oh, A. J., Ben-David, S., Azimov, N., Harkavy-Friedman, J. M., & Corcoran, C. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.009 · Cited by 55
“These can be targeted in high risk patients through medications other than antipsychotics (Cornblatt et al., 2007), and with psychosocial treatments such as cognitive-behavioral therapy (Addington et al.”
BackgroundSchizophrenia — an anxiety disorder?
Hall, J. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.195370 · Cited by 52
Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis
McAusland, L., & Addington, J. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12368 · Cited by 37
Morita, K., Kobayashi, H., Takeshi, K., Tsujino, N., Nemoto, T., & Mizuno, M. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12032 · Cited by 16
Metadata
- Authors
- Cornblatt, B. A., Lencz, T., Smith, C. W., Olsen, R., Auther, A. M., Nakayama, E., Lesser, M. L., Tai, J. Y., Shah, M. R., Foley, C. A., Kane, J. M., & Correll, C. U.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-04-15
- Volume
- 68
- Issue
- 04
- Pages
- 546-557
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2057646365
- Cited by
- 218
- References
- 0
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.